![]() |
|
|
Vol. 58, Issue 1, 120-128, July 2000
Departments of Pharmacology (S.P.L., B.F.O., G.V., S.R.G.), Psychiatry (G.Y.N.), and Medicine (S.R.G.), University of Toronto, Toronto, Ontario; Centre for Addiction and Mental Health (B.F.O., T.N., S.R.G.), Toronto, Ontario; and Mental Health Research Institute (H.A., A.M.), University of Michigan, Ann Arbor, Michigan
| |
Abstract |
|---|
|
|
|---|
Numerous mutant G protein-coupled receptors with diminished or no function have been described that are naturally occurring or that are the product of gene manipulation. It has largely been assumed that receptor mutants do not affect the function of the wild-type receptor; however, the occurrence of G protein-coupled receptor dimerization suggests the possibility that an intermolecular interaction between mutant and wild-type receptors can occur. We have shown previously that the D2 dopamine receptor (D2DR) exists as dimers in cell lines and brain tissue. In this study, we demonstrated that mutant D2DR can modulate the function of the wild-type D2DR. While attempting to elucidate the structure of the D2DR dimer, we demonstrated that nonfunctional D2DR substitution and truncation mutants antagonized wild-type D2DR function. Furthermore, from analyses of this interaction between the receptor mutants and the D2DR, using photoaffinity labeling, we provide evidence that the D2DR is oligomeric in the cell.
| |
Introduction |
|---|
|
|
|---|
Dopamine
receptors are G protein-coupled receptors (GPCRs) and have a
topological motif of seven hydrophobic
-helical domains that span
the lipid bilayer and are connected by extracellular and intracellular
loops. Until recently, mechanisms of GPCR ligand binding and signal
transduction have been modeled with the assumption that only monomeric
receptors participate in the processes. However, there is increasing
evidence that GPCRs exist as dimers. For instance, we have shown that
D1 and D2 dopamine receptors expressed in cell lines exist as
homodimers (Ng et al., 1994
; George et al., 1998
) and that D2 dopamine
receptors (D2DR) exist as dimers in human and rat brain tissue
(Zawarynski et al., 1998
). The M2 muscarinic (Maggio et al., 1993a
),
2-adrenergic (Hebert et al., 1996
), V2 vasopressin (Hebert et al., 1996
), metabotropic glutamate (Romano et
al., 1996
), H2 histamine (Fukushima et al., 1997
),
-opioid (Cvejic
and Devi, 1997
), D3 dopamine (Nimchinsky et al., 1997
), Ca2+-sensing (Bai et al., 1998
), and B2
bradykinin (AbdAlla et al., 1999
) receptors have also been shown to
form dimers, suggesting that dimerization may be a universal aspect of
GPCR biology. Furthermore, we have shown recently that two closely
related serotonin receptor subtypes, the 5-HT1B
and 5-HT1D receptors, form homodimers and undergo
heterodimeric assembly when coexpressed (Xie et al., 1999
). Hetero-oligomerization (Jones et al., 1998
; Kaupmann et al., 1998
; White et al., 1998
; Kuner et al., 1999
; Ng et al., 1999
) and
homo-oligomerization (Ng et al., 1999
) have also been shown to occur
between the metabotropic
-aminobutyric acid receptors
GABABR1 and GABABR2.
One of the first observations suggesting that a monomeric model may not
fully describe the mechanisms of GPCR function came from studies on
muscarinic/adrenergic receptor chimera (Maggio et al., 1993a
). Two
chimera, both incapable of binding muscarinic or adrenergic ligands
when expressed alone, recovered ligand binding properties when
coexpressed. It was postulated that the two chimera associated and
thereby reconstituted a ligand binding pocket. A similar study using
mutated type 1 angiotensin II receptors also showed recovery of ligand
binding, albeit low, on coexpression of receptors incapable of binding
when expressed alone (Monnot et al., 1996
). Based on these studies and
protein structure analysis, a model was proposed in which transmembrane
(TM) helices of GPCRs participate in domain swapping when in the
dimeric state, to explain how binding pockets are recovered in
binding-incapable GPCRs (Gouldson et al., 1997
). According to this
model, on receptor dimerization, the original binding pockets of the
two subunit monomers are replaced by the formation of two binding
pockets that are similar in structure to the monomeric receptor, except
that they are formed from regions donated by both monomers (see Fig.
1).
|
In this study, we examined TM domain swapping in D2DR dimerization,
using D2DR point mutants and D2DR truncation mutants containing TM
domains 1 to 5 or TM domains 6 and 7 (Fig.
2). We demonstrated that the mechanism of
D2DR dimerization does not involve TM domain swapping as predicted by
the above model. However, our observations using the mutant receptors
confirmed that there was intermolecular association among D2DRs and
showed that, because of this interaction, mutant D2DRs could antagonize
wild-type D2DRs when coexpressed. Moreover, our data indicated that
D2DR exists as oligomeric structures in the cell.
|
| |
Materials and Methods |
|---|
|
|
|---|
Construction of D2DR Point Mutants.
The Asp residue in TM
domain 3 (position 114) of the D2DR was mutated to Asn and is
designated Asp114Asn. In the second mutant, two
Ser residues in TM domain 5 (positions 194 and 197) were mutated to Ala
residues and are designated
Ser194Ala/Ser197Ala D2DR.
The construction of the Asp114Asn D2DR and
Ser194Ala/Ser197Ala D2DR
mutant receptors and their insertion into mammalian expression vectors
have been described previously (Mansour et al., 1992
).
Construction of D2DR and D2DR Fragment Expression Vectors. cDNA encoding the short isoform of the D2DR (kindly provided by Dr. O. Civelli, University of California Irvine, Irvine, CA) was used as the template in the polymerase chain reaction (PCR) construction of the cDNA constructs for the D2DR and the truncation mutants. The sequences (5' to 3') and designations of the oligonucleotides used were as follows: P191, GCAAGCTTGCCACCCAGTCGGTCCACCGC; P192, GCGCGGCCGCTCACTGAGTGGCTTTCTTCTCCTTCTG; P780, GCAAGCTTGCCGCCATGGAAAAGCGAGTCAACACCAAACGCAGCAGCCGAGC; P613, ACGCGGCCGCAGGCTGCTGTGCGGGCAGGCACGAGAGTCAGCAGTGGAGGATCTT.
The D2DR cDNA construct was generated using P191 and P613. The D2N cDNA that encoded amino acids 1 through 373 was generated using P191 and P192, and the D2C cDNA encoding amino acids 212 through 414 was generated using P780 and P613 (Fig. 2). PCR reactions utilized Pfu enzyme (Pharmacia, Piscataway, NJ) under the following conditions: 4-min precycle denaturation at 96°C followed by denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 2.5 min for 30 cycles. All three PCR products were inserted into the mammalian expression vector pcDNA3. The absence of sequence errors and correct orientation of the PCR products into the expression vector were verified by sequencing.Cell Culture and Transfection of Cells.
COS-7 monkey kidney
cells and Chinese hamster ovary (CHO) cells (American Type Culture
Collection, Manassas, VA) were maintained as monolayer cultures at
37°C in minimum essential medium supplemented with 10% fetal bovine
serum and antibiotics. COS-7 or CHO-K1 cells were transiently
transfected by the calcium phosphate precipitation method or by the use
of lipofectamine reagent (Life Technologies, Rockville, MD). When a
receptor, mutant receptor, or receptor fragment was expressed alone, an
equal amount of pcDNA3 vector was cotransfected with each construct, so
that the total amount of DNA used was consistent with studies involving
transfections with two constructs. When two constructs were used for
coexpression experiments, equal amounts of each construct were used
unless otherwise stated. For coexpression experiments in which the
amount of one construct used was variable, the total amount of DNA
transfected was kept constant by the addition of a compensating amount
of pcDNA3 vector. The full-length D2DR was also coexpressed with the
µ-opioid receptor or an orphan aminergic GPCR, putative
neurotransmitter receptor (PNR), the cloning of which has been reported
previously (Zeng et al., 1998
).
Membrane Preparation.
All tissues were washed extensively
with PBS. Cell lysate was prepared by polytron disruption in ice-cold 5 mM Tris-HCl, 2 mM EDTA buffer, containing 5 µg/ml leupeptin, 10 µg/ml benzamidine, and 5 µg/ml soybean trypsin inhibitor as
described previously (Ng et al., 1994
). Membrane protein was determined
by the Bradford assay according to the manufacturer's instructions
(BioRad, Hercules, CA).
Receptor Pharmacology.
Saturation binding experiments were
performed with ~20 µg of membrane protein with increasing
concentrations of [3H]spiperone or
[3H]nemonapride (also known as YM-09151-2)
(10-4000 pM, final concentration) and used to determine receptor
densities (Bmax) and affinities for ligands
(KD) as previously described (Ng et al.,
1996
). Competition experiments were done in triplicate in the absence
or presence of 5'-guanylimidodiphosphate (100 µM, final
concentration) with increasing concentrations of dopamine
(10
12 to 10
3
M). The concentration of radioligand used in the
competition assays was approximately equivalent to its
KD. Bound ligand was isolated by rapid
filtration through a Brandel 48-well cell harvester, using Whatman GF/C
filters. Data were analyzed by nonlinear least-squares regression,
using the computer-fitting program Prism version 2.01 (GraphPad).
Photoaffinity Labeling.
The precursor compounds for the
photoaffinity label
[125I]4-azido-5-iodo-nemonapride
([125I]azido-YM) and
125I-azidophenethyl-spiperone
(125I-azido-NAPS) were supplied by Research
Biochemicals Inc. (Natick, MA) as part of the Chemical Synthesis
Program of the National Institute of Mental Health. Radioiodination was
performed by NEN Life Science Products (Boston, MA). Photoaffinity
labeling was performed as described previously (Ng et al., 1996
).
Briefly, membranes prepared from D2DR-expressing cells were incubated
with [125I]azido-YM or
125I-azido-NAPS for 1.5 h. Specific binding
was defined by coincubation with 1 µM (+)-butaclamol. The mixture was
exposed to UV light to cross-link the photolabel compound, and the
membrane was collected and subjected to electrophoresis. The gel was
then fixed and exposed to film.
Adenylyl Cyclase Activity.
Adenylyl cyclase assays were
conducted essentially as described previously (Salomon et al., 1974
).
The assay mix contained 0.02 ml of membrane suspension (10-25 µg of
protein), 0.012 mM ATP, 0.1 mM cAMP, 0.053 mM GTP, 2.7 mM
phosphoenolpyruvate, 0.2 units of pyruvate kinase, 1 unit of myokinase,
1 µM forskolin, and 0.13 µCi of [32P]ATP in
a final volume of 0.05 ml. The mixture was incubated with
10
12 to 10
3 M dopamine
at 27°C for 20 min, and enzyme activities were determined. Data were
analyzed by computer-fitted nonlinear least-squares regression.
Electrophoresis and Immunoblot Analysis.
In brief, tissues
were solubilized in sample buffer consisting of 50 mM Tris-HCl (pH
6.5), 1% SDS, 10% glycerol, 0.003% bromophenol blue, and 10%
2-mercaptoethanol. The samples were subjected to polyacrylamide gel
electrophoresis with 12% acrylamide gels and electroblotted onto
nitrocellulose as previously described (Ng et al., 1996
). Unless
otherwise indicated, D2DR immunoreactivity was revealed with the rabbit
polyclonal antibody, which was raised against a 120-amino acid sequence
(aa 221-340) in the third intracellular loop of the human D2DR (Levey
et al., 1993
). The antibody, designated AL-26, was a generous gift from
Dr. Mark R. Brann (Acadia Pharmaceuticals Inc., San Diego, CA). An
antibody recognizing the N terminus of the human D2DR, N-19 (Santa Cruz
Biotechnology, Santa Cruz, CA), was also used.
Densitometry. The relative intensities of bands visualized by immunostaining and in autoradiograms were determined using reflective densitometry and the Gel Doc 1000 Video Documentation System and Molecular Analyst software (BioRad).
| |
Results |
|---|
|
|
|---|
Coexpression of Asp114Asn and
Ser194Ala/Ser197Ala D2DR Mutants.
Radioligand binding with the agonists
[3H]dopamine and
[3H]N-propyl-apomorphine and with
the antagonist [3H]nemonapride was undetectable
in cells expressing Asp114Asn D2DR (Fig.
3). In cells expressing the
Ser194Ala/Ser197Ala D2DR,
agonist binding was diminished compared with wild-type D2DR, but
nemonapride binding was not significantly different (Fig. 3). These
binding characteristics are consistent with previous studies on these
D2DR mutants (Mansour et al., 1992
). We hypothesized that, as a result
of TM domain swapping, the number of detected binding sites would
increase on coexpression of Asp114Asn D2DR with
Ser194Ala/Ser197Ala D2DR
because of the reconstitution of intact binding pockets (Fig. 1D).
However, when the point mutants were coexpressed, radioligand-detected receptor density was significantly diminished compared with that of
cells only expressing
Ser194Ala/Ser197Ala D2DR.
Photoaffinity labeling with [125I]azido-YM
(Fig. 4) was consistent with the
radioligand binding data. Densitometry showed that labeling of receptor
monomer was reduced by ~60% in cells coexpressing
Asp114Asn D2DR and
Ser194Ala/Ser197Ala D2DR
compared with cells expressing
Ser194Ala/Ser197Ala D2DR
alone and that there was a ~70% reduction in labeling of the
receptor dimer. Because the number of ligand binding sites was not
increased or even maintained, it was concluded that that the model of
TM domains 1 to 4 swapping with TM domains 5 to 7, although adequate to
explain the results obtained with the angiotensin II receptor (Monnot
et al., 1996
; Gouldson et al., 1997
), does not accurately describe
dimerization in the D2DR.
|
|
Coexpression of Asp114Asn D2DR and Wild-Type D2DR.
Because coexpression of the Asp114Asn D2DR with
the Ser194Ala/Ser197/Ala
D2DR decreased the radioligand-detected receptor density, we examined
the effects of Asp114Asn D2DR on the wild-type
receptor. When Asp114Asn D2DR was coexpressed
with wild-type D2DR, radioligand-detected receptor density was
attenuated (Fig. 5). As the ratio of
Asp114Asn D2DR cDNA to wild-type D2DR cDNA used
for transfection increased, the degree of binding inhibition also
increased.
|
N-Terminal and C-Terminal D2DR Fragments Are Properly Processed and
Trafficked.
To determine whether TM domains 1 to 5 participated in
domain swapping with TM domains 6 to 7, we used a strategy involving receptor fragments. However, it was necessary to demonstrate that receptor fragments were properly folded and capable of mimicking the
appropriate portions of the wild-type receptor. D2N, which includes TM
domains 1 to 5, or D2C, which includes TM domains 6 and 7 (see Fig. 2),
were transiently expressed separately in COS-7 cells. Immunoblot
analyses of membranes from these cells (Fig.
6) revealed that D2N and D2C were highly
expressed and trafficked to the cell surface. In membranes from cells
expressing D2N, bands of ~40 kDa, ~55 kDa, and ~75 kDa were
detected (Fig. 6, lane 1). The immunoreactive species of ~75 kDa
represented the glycosylated form of this truncated receptor, and the
~40 kDa and ~55 kDa bands likely represented nonglycosylated or
partially glycosylated receptor. The addition of ~35 kDa is
consistent with the molecular weight change in the full-length D2DR due
to glycosylation (Grigoriadis et al., 1988
). An immunoreactive band of
~35 kDa representing D2C was observed in membranes from cells
expressing D2C (Fig. 6, lane 2). No higher molecular weight species
were present, because D2C does not have any N-linked glycosylation
sites.
|
|
|
|
Coexpression of D2N and Asp114Asn D2DR.
We
predicted that if domain swapping of TM domains 1 to 5 with TM domains
6 and 7 occurred as postulated for the muscarinic/adrenergic receptor
chimera (Maggio et al., 1993a
; Gouldson et al., 1997
), coexpression of
D2N with Asp114Asn would result in the recovery
of D2DR binding (Fig. 10). Functional rescue of a defective mutant V2 vasopressin receptor has been shown by
coexpression of a truncation mutant (Schoneberg et al., 1996
). To
determine whether the coexpression of Asp114Asn
D2DR with D2N could result in the recovery of ligand binding, cells
coexpressing the receptor fragment and the point mutant were subjected
to saturation binding assays using
[3H]N-propyl-apomorphine and
[3H]nemonapride. No specific binding was
detected (data not shown), indicating that TM domains 1 to 5 do not
participate in swapping with TM domains 6 and 7 in the D2DR.
|
Coexpression of Full-Length D2DR with the Truncated Receptors
Inhibited Receptor Function.
Coexpression of the full-length D2DR
with either the D2N or D2C in COS-7 cells resulted in a significant
reduction in [3H]spiperone and
[3H]nemonapride binding (Table
1). This antagonism increased as the ratio of
receptor fragment to D2DR increased (Fig.
11). A reduction in photoaffinity
ligand binding in the presence of receptor fragment was also observed.
An almost complete attenuation of azido-NAPS binding was observed in
photolabeled membranes coexpressing the D2DR with either D2N or D2C
(Fig. 12A, lanes 5 and 7). Radioligand binding to the D2DR was not altered when membranes from cells expressing only D2DR were mixed with membranes from cells expressing only D2N or D2C (data not shown).
|
|
|
|
Coexpression of the D2DR with Another GPCR.
To determine
whether the antagonism by the receptor fragments or receptor mutant was
due to the cotransfection with the cDNA of a related membrane protein,
cells were cotransfected with D2DR cDNA and the cDNA for µ-opioid
receptor or an orphan GPCR, PNR (Zeng et al., 1998
). Radioligand
binding, photoaffinity labeling, and adenylyl cyclase inhibition by
dopamine were not significantly different in
membranes from cells transfected with D2DR cDNA and plasmid DNA
compared with membranes from cells cotransfected with D2DR cDNA and
µ-opioid receptor cDNA or PNR cDNA (data not shown).
| |
Discussion |
|---|
|
|
|---|
In this study we have shown that coexpression of a mutant D2DR
incapable of receptor function with the wild-type D2DR results in
attenuation of binding and function of the wild-type receptor. It was
observed that coexpression of the Asp114Asn D2DR
with the
Ser194Ala/Ser197Ala D2DR
decreased the radioligand-detected receptor density. We therefore
postulated that nonfunctional receptors may act as antagonists of
wild-type receptors. To further test this, the Asp114Asn D2DR, D2N, and D2C were each
coexpressed with wild-type D2DR. In each case, receptor function was
attenuated, compared with the wild-type receptor expressed alone, in an
expression-dependent manner. There are numerous reports of mutant and
truncated GPCRs that have diminished or no function, both as naturally
occurring phenomena and as the result of gene manipulation. However,
there are few reports concerning the coexpression of these mutant
receptors with the wild-type receptor. It has been demonstrated that a
truncation mutant of the human chemokine receptor 5 (CCR5) can inhibit
CCR5-mediated human immunodeficiency virus infection in individuals who
are heterozygous for the mutant GPCR (Benkirane et al., 1997
).
Recently, antagonism of the V2 vasopressin receptor by receptor
fragments has been shown (Zhu and Wess, 1998
).
In our studies, photoaffinity labeling of membranes where the D2DR was coexpressed with D2N or D2C revealed that the number of monomeric binding sites was markedly reduced (Fig. 8A). It was shown that this loss of binding sites was not the result of indirect effects on protein processing pathways (Fig. 13). This suggested that direct interactions between the D2DR and the mutant receptor resulted in the loss of receptor function and/or a reduced efficiency in trafficking of the wild-type receptor to the cell surface. One would expect that if a proportion of the D2DR functioned in the cell in a monomeric state, trafficking and function of the D2DR monomers would be unaffected by the presence of the receptor fragment. However, because cell surface expression of the receptor monomer was decreased, it can be concluded that the D2DRs do not function as monomers. Therefore, it can be inferred that D2DRs exist only as oligomers in the cell and that the detection of a receptor species corresponding in molecular weight to a receptor monomer may be the result of dissociation of the oligomer during electrophoresis.
A similar conclusion that D2DRs exist as oligomers can be drawn from the point mutant D2DR coexpression. The mutant Asp114Asn D2DR is incapable of binding ligand because of the substitution of the critical amino acid in TM domain 3. When this mutant was coexpressed with Ser194Ala/Ser197Ala D2DR, which, when expressed alone, bound antagonist with high affinity, the number of binding sites was decreased. In this case also, photoaffinity labeling confirmed attenuated binding to both dimeric and monomeric binding sites. This indicated that the function of the visualized monomeric and dimeric Ser194Ala/Ser197Ala D2DR was impaired. Therefore, one must conclude that the monomers, as well as the receptor dimers, were associated with the nonbinding mutant receptor in the cell, suggesting that the association of a binding-incapable receptor mutant with a binding-intact receptor mutant caused the loss of function. Thus our data suggest that an oligomeric array of intact receptors is necessary for normal function.
The possibility that the D2DR exists only as oligomeric complexes in
the cell is not unexpected. It has been predicted, based on radioligand
binding data, that there is cooperation between the binding sites in
the muscarinic receptor, which can be explained if the receptors exist
as oligomers (Wreggett and Wells, 1995
; Chidiac et al., 1997
). It has
been shown that multiple TM domain-spanning proteins such as the band 3 erythrocyte protein exist in large oligomeric arrays on the cell
surface (Casey and Reithmeier, 1991
). Furthermore, it is thought that G
proteins may also exist in large oligomeric structures (Jahangeer and
Rodbell, 1993
). Oligomerization and the disruption of cell surface
targeting may be the mechanism by which the mutant receptor antagonism occurs.
Our future studies will attempt to elucidate the precise sites of interaction involved in GPCR dimerization. It will be interesting to determine whether more than one mechanism is involved in the formation of receptor oligomers. Understanding dimerization may provide key insights into diseases involving both functional and defective GPCRs.
In summary, we have shown that TM domain swapping does not appear to occur in D2DR dimerization. Furthermore, we demonstrated that when a D2DR fragment was expressed with the full-length D2DR, or a mutant receptor incapable of ligand binding was coexpressed with the wild-type D2DR, receptor function was antagonized. We conclude that this disruption of the functional receptor is the result of an interaction between the receptor mutant and the D2DR that results from a disturbance in the ordering of the oligomeric receptor complex and a failure to efficiently express on the cell surface. A properly arranged oligomeric complex appeared to be required for D2DR trafficking. Therefore, we propose that active D2DR only exists as oligomers in the cell.
| |
Acknowledgment |
|---|
We thank Regina Cheng for technical assistance.
| |
Footnotes |
|---|
Received November 5, 1999; Accepted March 28, 2000
1 Current address: Merck Frosst Center for Therapeutic Research, Kirkland, QC H9H 3L1, Canada.
2 Current address: Pharmaco Genesis, 6628 Heather Heath Lane, West Bloomfield, MI, 48322.
This work was supported by grants from the Medical Research Council of Canada, the National Institute on Drug Abuse, the Smokeless Tobacco Research Council, an Addiction Research Foundation Fellowship to S.P.L., and a Medical Research Council of Canada Fellowship to G.N.
Send reprint requests to: Dr. Susan R. George, Department of Pharmacology, University of Toronto, Room 4358, Medical Sciences Blgd., 1 King's College Circle, Toronto, ON M5S 1A8, Canada. E-mail: s.george{at}utoronto.ca.
| |
Abbreviations |
|---|
GPCR, G protein-coupled receptor; D2DR, D2 dopamine receptor; TM, transmembrane; D2N, N terminus-truncated D2DR fragment (amino acids 1-373); D2C, C terminus-truncated D2DR fragment (amino acids 212-414); PCR, polymerase chain reaction; CHO, Chinese hamster ovary; PNR, putative neurotransmitter receptor; azido-YM, 4-azido-5-iodo-nemonapride; azido-NAPS, azidophenethyl-spiperone; CCR5, human chemokine receptor 5.
| |
References |
|---|
|
|
|---|
32.
J Biol Chem
272:
30603-30606
2-adrenergic receptor that exploits the domain structure of G protein-coupled receptors.
J Med Chem
40:
3871-3886[Medline].This article has been cited by other articles:
![]() |
P.-A. Vidi, B. R. Chemel, C.-D. Hu, and V. J. Watts Ligand-Dependent Oligomerization of Dopamine D2 and Adenosine A2A Receptors in Living Neuronal Cells Mol. Pharmacol., September 1, 2008; 74(3): 544 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chakera, R. M. Seeber, A. E. John, K. A. Eidne, and D. R. Greaves The Duffy Antigen/Receptor for Chemokines Exists in an Oligomeric Form in Living Cells and Functionally Antagonizes CCR5 Signaling through Hetero-Oligomerization Mol. Pharmacol., May 1, 2008; 73(5): 1362 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Szidonya, M. Cserzo, and L. Hunyady Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions J. Endocrinol., March 1, 2008; 196(3): 435 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. So, V. Verma, B. F. O'Dowd, and S. R. George Desensitization of the Dopamine D1 and D2 Receptor Hetero-Oligomer Mediated Calcium Signal by Agonist Occupancy of Either Receptor Mol. Pharmacol., August 1, 2007; 72(2): 450 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Free, L. A. Hazelwood, D. M. Cabrera, H. N. Spalding, Y. Namkung, M. L. Rankin, and D. R. Sibley D1 and D2 Dopamine Receptor Expression Is Regulated by Direct Interaction with the Chaperone Protein Calnexin J. Biol. Chem., July 20, 2007; 282(29): 21285 - 21300. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Thomas, C. A. Nechamen, J. E. Mazurkiewicz, M. Muda, S. Palmer, and J. A. Dias Follice-Stimulating Hormone Receptor Forms Oligomers and Shows Evidence of Carboxyl-Terminal Proteolytic Processing Endocrinology, May 1, 2007; 148(5): 1987 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Drake, S. K. Shenoy, and R. J. Lefkowitz Trafficking of G Protein-Coupled Receptors Circ. Res., September 15, 2006; 99(6): 570 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. C. Kong, T. Fan, G. Varghese, B. F. O'Dowd, and S. R. George Agonist-Induced Cell Surface Trafficking of an Intracellularly Sequestered D1 Dopamine Receptor Homo-Oligomer Mol. Pharmacol., July 1, 2006; 70(1): 78 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Bakker, A. F. Lozada, A. van Marle, F. C. Shenton, G. Drutel, K. Karlstedt, M. Hoffmann, M. Lintunen, Y. Yamamoto, R. M. van Rijn, et al. Discovery of Naturally Occurring Splice Variants of the Rat Histamine H3 Receptor That Act as Dominant-Negative Isoforms Mol. Pharmacol., April 1, 2006; 69(4): 1194 - 1206. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Herrick-Davis, E. Grinde, T. J. Harrigan, and J. E. Mazurkiewicz Inhibition of Serotonin 5-Hydroxytryptamine2C Receptor Function through Heterodimerization: RECEPTOR DIMERS BIND TWO MOLECULES OF LIGAND AND ONE G-PROTEIN J. Biol. Chem., December 2, 2005; 280(48): 40144 - 40151. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fan, G. Varghese, T. Nguyen, R. Tse, B. F. O'Dowd, and S. R. George A Role for the Distal Carboxyl Tails i |